Answers are grounded in this paper and cite their sources.
Ischemia and reperfusion (I/R) injury permeates a variety of diseases, causing significant inflammatory and thrombotic responses. Given its importance, efforts have been made to identify the complex and integrated network of mediators that ensure a timely and spatially regulated inflammatory response, in order to mitigate its deleterious effects on the body. The Annexin A1 protein (ANXA1) and its mimetic peptide Ac2-26 can alleviate the inflammatory process by decreasing adhesion and neutrophil trafficking, inhibiting pro-inflammatory and pro-thrombotic mediators, and regulating the interactions of neutrophil-platelets. In this review, we discuss the anti-inflammatory potential of ANXA1 and its intracellular effects, contrasting the possible long-term permanence of the damage caused by I/R injuries. As a pharmacological approach, the aim is to understand how ANXA1 operates in processes resulting from I/R injuries and its performance as a biomarker and therapeutic target after injury in different tissues and organs.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: